Hearing Loss After Radiotherapy for Pediatric Brain Tumors

Effect of Cochlear Dose

Chiaho Hua, Johnnie K. Bass, Raja Khan, Larry E. Kun, Thomas E. Merchant

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Purpose: To determine the effect of cochlear dose on sensorineural hearing loss in pediatric patients with brain tumor treated by using conformal radiation therapy (CRT). Patients and Methods: We studied 78 pediatric patients (155 ears) with localized brain tumors treated in 1997-2001 who had not received platinum-based chemotherapy and were followed up for at least 48 months. They were evaluated prospectively by means of serial pure-tone audiograms (250 Hz-8 kHz) and/or auditory brainstem response before and every 6 months after CRT. Results: Hearing loss occurred in 14% (11 of 78) of patients and 11% (17 of 155) of cochleae, with onset most often at 3-5 years after CRT. The incidence of hearing loss was low for a cochlear mean dose of 30 Gy or less and increased at greater than 40-45 Gy. Risk was greater at high frequencies (6-8 kHz). In children who tested abnormal for hearing, average hearing thresholds increased from a less than 25 decibel (dB) hearing level (HL) at baseline to a mean of 46 ± 13 (SD) dB HL for high frequencies, 41 ± 7 dB HL for low frequencies, and 38 ± 6 dB HL for intermediate frequencies. Conclusions: Sensorineural hearing loss is a late effect of CRT. In the absence of other factors, including ototoxic chemotherapy, increase in cochlear dose correlates positively with hearing loss in pediatric patients with brain tumor. To minimize the risk of hearing loss for children treated with radiation therapy, a cumulative cochlear dose less than 35 Gy is recommended for patients planned to receive 54-59.4 Gy in 30-33 treatment fractions.

Original languageEnglish (US)
Pages (from-to)892-899
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume72
Issue number3
DOIs
StatePublished - Nov 1 2008

Fingerprint

auditory defects
Cochlea
hearing
Hearing Loss
Brain Neoplasms
Hearing
brain
radiation therapy
Radiotherapy
tumors
Pediatrics
dosage
Sensorineural Hearing Loss
chemotherapy
Drug Therapy
cochlea
intermediate frequencies
Brain Stem Auditory Evoked Potentials
ear
Platinum

Keywords

  • Cochlear dose
  • Dose effect
  • Hearing loss
  • Pediatric brain tumor
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Hearing Loss After Radiotherapy for Pediatric Brain Tumors : Effect of Cochlear Dose. / Hua, Chiaho; Bass, Johnnie K.; Khan, Raja; Kun, Larry E.; Merchant, Thomas E.

In: International Journal of Radiation Oncology Biology Physics, Vol. 72, No. 3, 01.11.2008, p. 892-899.

Research output: Contribution to journalArticle

Hua, Chiaho ; Bass, Johnnie K. ; Khan, Raja ; Kun, Larry E. ; Merchant, Thomas E. / Hearing Loss After Radiotherapy for Pediatric Brain Tumors : Effect of Cochlear Dose. In: International Journal of Radiation Oncology Biology Physics. 2008 ; Vol. 72, No. 3. pp. 892-899.
@article{8fbecfcf81a840119c7ae2babbf45cf2,
title = "Hearing Loss After Radiotherapy for Pediatric Brain Tumors: Effect of Cochlear Dose",
abstract = "Purpose: To determine the effect of cochlear dose on sensorineural hearing loss in pediatric patients with brain tumor treated by using conformal radiation therapy (CRT). Patients and Methods: We studied 78 pediatric patients (155 ears) with localized brain tumors treated in 1997-2001 who had not received platinum-based chemotherapy and were followed up for at least 48 months. They were evaluated prospectively by means of serial pure-tone audiograms (250 Hz-8 kHz) and/or auditory brainstem response before and every 6 months after CRT. Results: Hearing loss occurred in 14{\%} (11 of 78) of patients and 11{\%} (17 of 155) of cochleae, with onset most often at 3-5 years after CRT. The incidence of hearing loss was low for a cochlear mean dose of 30 Gy or less and increased at greater than 40-45 Gy. Risk was greater at high frequencies (6-8 kHz). In children who tested abnormal for hearing, average hearing thresholds increased from a less than 25 decibel (dB) hearing level (HL) at baseline to a mean of 46 ± 13 (SD) dB HL for high frequencies, 41 ± 7 dB HL for low frequencies, and 38 ± 6 dB HL for intermediate frequencies. Conclusions: Sensorineural hearing loss is a late effect of CRT. In the absence of other factors, including ototoxic chemotherapy, increase in cochlear dose correlates positively with hearing loss in pediatric patients with brain tumor. To minimize the risk of hearing loss for children treated with radiation therapy, a cumulative cochlear dose less than 35 Gy is recommended for patients planned to receive 54-59.4 Gy in 30-33 treatment fractions.",
keywords = "Cochlear dose, Dose effect, Hearing loss, Pediatric brain tumor, Radiation therapy",
author = "Chiaho Hua and Bass, {Johnnie K.} and Raja Khan and Kun, {Larry E.} and Merchant, {Thomas E.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1016/j.ijrobp.2008.01.050",
language = "English (US)",
volume = "72",
pages = "892--899",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Hearing Loss After Radiotherapy for Pediatric Brain Tumors

T2 - Effect of Cochlear Dose

AU - Hua, Chiaho

AU - Bass, Johnnie K.

AU - Khan, Raja

AU - Kun, Larry E.

AU - Merchant, Thomas E.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Purpose: To determine the effect of cochlear dose on sensorineural hearing loss in pediatric patients with brain tumor treated by using conformal radiation therapy (CRT). Patients and Methods: We studied 78 pediatric patients (155 ears) with localized brain tumors treated in 1997-2001 who had not received platinum-based chemotherapy and were followed up for at least 48 months. They were evaluated prospectively by means of serial pure-tone audiograms (250 Hz-8 kHz) and/or auditory brainstem response before and every 6 months after CRT. Results: Hearing loss occurred in 14% (11 of 78) of patients and 11% (17 of 155) of cochleae, with onset most often at 3-5 years after CRT. The incidence of hearing loss was low for a cochlear mean dose of 30 Gy or less and increased at greater than 40-45 Gy. Risk was greater at high frequencies (6-8 kHz). In children who tested abnormal for hearing, average hearing thresholds increased from a less than 25 decibel (dB) hearing level (HL) at baseline to a mean of 46 ± 13 (SD) dB HL for high frequencies, 41 ± 7 dB HL for low frequencies, and 38 ± 6 dB HL for intermediate frequencies. Conclusions: Sensorineural hearing loss is a late effect of CRT. In the absence of other factors, including ototoxic chemotherapy, increase in cochlear dose correlates positively with hearing loss in pediatric patients with brain tumor. To minimize the risk of hearing loss for children treated with radiation therapy, a cumulative cochlear dose less than 35 Gy is recommended for patients planned to receive 54-59.4 Gy in 30-33 treatment fractions.

AB - Purpose: To determine the effect of cochlear dose on sensorineural hearing loss in pediatric patients with brain tumor treated by using conformal radiation therapy (CRT). Patients and Methods: We studied 78 pediatric patients (155 ears) with localized brain tumors treated in 1997-2001 who had not received platinum-based chemotherapy and were followed up for at least 48 months. They were evaluated prospectively by means of serial pure-tone audiograms (250 Hz-8 kHz) and/or auditory brainstem response before and every 6 months after CRT. Results: Hearing loss occurred in 14% (11 of 78) of patients and 11% (17 of 155) of cochleae, with onset most often at 3-5 years after CRT. The incidence of hearing loss was low for a cochlear mean dose of 30 Gy or less and increased at greater than 40-45 Gy. Risk was greater at high frequencies (6-8 kHz). In children who tested abnormal for hearing, average hearing thresholds increased from a less than 25 decibel (dB) hearing level (HL) at baseline to a mean of 46 ± 13 (SD) dB HL for high frequencies, 41 ± 7 dB HL for low frequencies, and 38 ± 6 dB HL for intermediate frequencies. Conclusions: Sensorineural hearing loss is a late effect of CRT. In the absence of other factors, including ototoxic chemotherapy, increase in cochlear dose correlates positively with hearing loss in pediatric patients with brain tumor. To minimize the risk of hearing loss for children treated with radiation therapy, a cumulative cochlear dose less than 35 Gy is recommended for patients planned to receive 54-59.4 Gy in 30-33 treatment fractions.

KW - Cochlear dose

KW - Dose effect

KW - Hearing loss

KW - Pediatric brain tumor

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=52949143048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949143048&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.01.050

DO - 10.1016/j.ijrobp.2008.01.050

M3 - Article

VL - 72

SP - 892

EP - 899

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -